Akebia Therapeutics (AKBA) Enterprise Value (2013 - 2026)
Akebia Therapeutics (AKBA) reported Enterprise Value of -$162.6 million for Q1 2026, down 43.39% year-over-year from -$287.2 million in Q1 2025, and up 12.03% quarter-over-quarter from -$184.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Enterprise Value (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 14 years of Enterprise Value data on file, last reported at -$162.6 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$162.6 million, down 43.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$162.6 million (down 43.39% YoY), and the FY2025 annual result was -$184.8 million, down 256.36% from the prior year.
- Enterprise Value grew to -$162.6 million in Q1 2026 per AKBA's latest filing, from -$184.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$34.0 million in Q3 2024 and troughed at -$184.8 million in Q4 2025.
- A 5-year average of -$99.2 million and a median of -$90.5 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value jumped 67.87% in 2023, then slumped 389.14% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$90.5 million in 2022, then soared by 52.55% to -$42.9 million in 2023, then decreased by 20.84% to -$51.9 million in 2024, then sank by 256.36% to -$184.8 million in 2025, then climbed by 12.03% to -$162.6 million in 2026.
- Business Quant data shows AKBA's Enterprise Value at -$162.6 million in Q1 2026, -$184.8 million in Q4 2025, and -$166.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -2.15 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -77.77 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -1.32 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -511.86 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -750.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -498.58 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | -162.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -162.60 Mn |
| Dec 31, 2025 | -184.84 Mn |
| Sep 30, 2025 | -166.40 Mn |
| Jun 30, 2025 | -137.31 Mn |
| Mar 31, 2025 | -113.40 Mn |
| Dec 31, 2024 | -51.87 Mn |
| Sep 30, 2024 | -34.02 Mn |
| Jun 30, 2024 | -39.50 Mn |
| Mar 31, 2024 | -41.96 Mn |
| Dec 31, 2023 | -42.93 Mn |
| Sep 30, 2023 | -46.53 Mn |
| Jun 30, 2023 | -53.60 Mn |
| Mar 31, 2023 | -57.00 Mn |
| Dec 31, 2022 | -90.47 Mn |
| Sep 30, 2022 | -144.80 Mn |
| Jun 30, 2022 | -143.90 Mn |
| Mar 31, 2022 | -174.56 Mn |
| Dec 31, 2021 | -149.80 Mn |
| Sep 30, 2021 | -207.20 Mn |
| Jun 30, 2021 | -246.99 Mn |